Skip to content

Clinical trials

Phase 4 Acquired Immunodeficiency Syndrome trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Acquired Immunodeficiency Syndrome Phase: Phase 4 Country / region: United States Clear all

81 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20022
20041
20056
20065
20073
20087
20095
20103
20115
20134
20153
20161
20176
20183
20195
20204
20214
20222
20232
20241
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed55
Terminated13
Recruiting5
Withdrawn4
Unknown status2
Active, not recruiting1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Community Research Initiative of New England5
Emory University4
University of California, San Francisco4
National Institute of Allergy and Infectious Diseases (NIAID)3
University of Maryland, Baltimore3
ViiV Healthcare3
Astra USA2
Bristol-Myers Squibb2
Midland Research Group, Inc.2
New York State Psychiatric Institute2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Acquired Immunodeficiency Syndrome81
HIV Infections33
Hepatitis C8
Opioid-Related Disorders4
Substance-Related Disorders4
Fatigue3
Cardiovascular Diseases2
Cytomegalovirus Infections2
Diabetes Mellitus2
Dyslipidemias2

Trials

Showing 1 to 25 of 81. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.